Latest Exact Sciences Corp (EXAS) Headlines
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
'Mad Money' Lightning Round: I Like Verizon Over AT&T
at The Street - Wed Mar 05, 5:00AM CST
Cramer thinks Exact Sciences is a good stock byt he's avoiding Synovus Financial.
Jim Cramer's 'Mad Money' Recap: Stocks on Sale
at The Street - Tue Mar 04, 7:08PM CST
It was Mardi Gras on Wall Street today after Monday's drop, which created a one-day sale on great stocks, Cramer says.
Exact Sciences to Participate in ROTH Conference
Business Wire - Mon Mar 03, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the 26th Annual ROTH Conference.
Exact Sciences (EXAS) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:51AM CST
Exact Sciences Corporation was a big mover last session, as its shares rose over 5% on the day.
Exact Sciences Reports Fourth-Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Feb 20, 6:30AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the quarter and year ended Dec. 31, 2013.
Numera's Social Engagement Platform Deployed by Omron Healthcare
Business Wire - Tue Feb 18, 5:00AM CST
Numera today announced Omron Healthcare has launched Omron Bi-LINK(TM), based on Numera's Social(TM) engagement platform, giving consumers the ability to upload and interact with data captured on Omron medical devices.
Exact Sciences to Host Fourth-Quarter 2013 Results Webcast and Call
Business Wire - Mon Feb 10, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss its fourth-quarter 2013 financial results on Feb. 20, 2014.
U.S. Food and Drug Administration confirms date for Exact Sciences' advisory committee
Business Wire - Wed Feb 05, 8:00AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration has confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the company's Cologuard stool-DNA-based, non-invasive colorectal cancer screening test on March 27, 2014. The Federal Register notice can be found by clicking here.
Exact Sciences to participate in Leerink Swann Global Healthcare Conference
Business Wire - Tue Feb 04, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Leerink Swann Global Healthcare Conference.
Uptrend Call Working As Exact Sciences Stock Rises 24.0% (EXAS)
Comtex SmarTrend(R) - Wed Jan 22, 9:28AM CST
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on November 26th, 2013 at $12.00. In approximately 2 months, Exact Sciences has returned 24.00% as of today's recent price of $14.88.
'Mad Money' Lightning Round: BB&T Is Fantastic
at The Street - Thu Jan 09, 5:00AM CST
Cramer has to wait and see about Michael Kors, he's not backing away from Franks International but he does not like Universal Display.
Jim Cramer's 'Mad Money' Recap: The Analysts Are Wrong
at The Street - Wed Jan 08, 7:00PM CST
They're trying to get you out of stocks at the very time you should be staying in, Cramer says.
2013 Report on the In-Vitro Diagnostic Substance Manufacturing Industry Features Players such as Hologic, Inc. and Quidel Corporation
M2 - Tue Jan 07, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dvwjc/invitro) has announced the addition of Supplier Relations US, LLC's new report "In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. The industry's revenue for the year 2012 was reported at $12.6 billion USD, with an estimated gross profit of 43.66%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $19.6 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. This 2013 year-end publication of In-Vitro Diagnostic Substance Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. At 173 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. This current report contains shipment data, inventory levels, international trade volume, and industry specific price indices available through September 2013. Industry analysts and Fortune 500 customers rely on this quarterly report to make accurate forecasts and planning in today's uncertain economy. Companies Mentioned: - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/7dvwjc/invitro Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 06, 3:14PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the J.P. Morgan Healthcare Conference.
Investors are betting against EXACT Sciences Corporation (EXAS), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:00AM CST
Investors are betting against EXACT Sciences Corporation (EXAS), Should You?
Look for Shares of Exact Sciences to Potentially Rebound after Yesterday's 4.32% Sell Off
Comtex SmarTrend(R) - Tue Dec 31, 5:35PM CST
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $11.53 to a high of $12.21. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $12.07 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Exelixis, Inc. (NASDAQ: EXEL), Cempra, Inc. (NASDAQ: CEMP), Exact Sciences Corporation (NASDAQ: EXAS), and Onconova Therapeutics, Inc. (NASDAQ: ONTX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Global Molecular Diagnostics in Cancer Testing: Market Report 2013
M2 - Tue Dec 17, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/wln6dv/molecular) has announced the addition of the "Global Molecular Diagnostics in Cancer Testing: Market Report 2013" report to their offering. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. "Global Molecular Diagnostics in Cancer Testing: Market Report 2013", describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The data also analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 5.1 Technology and Market Trends 5.2 M&A Activity 5.3 Partnerships 5.4 Competitive Analysis 5.5 SWOT Comparison of Business Models for Cancer Diagnostic Testing 5.6 Intellectual Property Rights 6. Reimbursement and Billing 6.1 Overview 6.3 Breast Cancer Tests 6.4 Colon Cancer Tests 6.5 Trends in Patient Care and Reimbursement 6.6 Revenue Threats 6.7 Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned: - Agendia - ArcticDx, Inc - Biodesix - bioTheranostics (AviaraDx) - Cancer Genetics, Inc - Clarient, Inc (GE Healthcare) - CombiMatrix Corporation - Epigenomics - Exact Sciences Corporation - Exagen Diagnostics, Inc - Exiqon - Ferrer inCode - Genomic Health, Inc - Genoptix, Inc - InterGenetics, Inc - LabCorp - Myriad Genetics, Inc - Nanostring - Neogenomics - Nuvera Biosciences - Orion Genomics - QIAGEN NV - Rosetta Genomics Ltd - Seegene - Sequenom, Inc - SABiosciences Corporation (Qiagen) - Source MDx - Targeted Molecular Diagnostics For more information visit http://www.researchandmarkets.com/research/wln6dv/molecular
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
'Mad Money' Lightning Round: I Like Verizon Over AT&T
at The Street - Wed Mar 05, 5:00AM CST
Cramer thinks Exact Sciences is a good stock byt he's avoiding Synovus Financial.
Jim Cramer's 'Mad Money' Recap: Stocks on Sale
at The Street - Tue Mar 04, 7:08PM CST
It was Mardi Gras on Wall Street today after Monday's drop, which created a one-day sale on great stocks, Cramer says.
Exact Sciences to Participate in ROTH Conference
Business Wire - Mon Mar 03, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the 26th Annual ROTH Conference.
Exact Sciences (EXAS) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:51AM CST
Exact Sciences Corporation was a big mover last session, as its shares rose over 5% on the day.
Exact Sciences Reports Fourth-Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Feb 20, 6:30AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the quarter and year ended Dec. 31, 2013.
Numera's Social Engagement Platform Deployed by Omron Healthcare
Business Wire - Tue Feb 18, 5:00AM CST
Numera today announced Omron Healthcare has launched Omron Bi-LINK(TM), based on Numera's Social(TM) engagement platform, giving consumers the ability to upload and interact with data captured on Omron medical devices.
Exact Sciences to Host Fourth-Quarter 2013 Results Webcast and Call
Business Wire - Mon Feb 10, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss its fourth-quarter 2013 financial results on Feb. 20, 2014.
U.S. Food and Drug Administration confirms date for Exact Sciences' advisory committee
Business Wire - Wed Feb 05, 8:00AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration has confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the company's Cologuard stool-DNA-based, non-invasive colorectal cancer screening test on March 27, 2014. The Federal Register notice can be found by clicking here.
Exact Sciences to participate in Leerink Swann Global Healthcare Conference
Business Wire - Tue Feb 04, 3:30PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Leerink Swann Global Healthcare Conference.
Uptrend Call Working As Exact Sciences Stock Rises 24.0% (EXAS)
Comtex SmarTrend(R) - Wed Jan 22, 9:28AM CST
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on November 26th, 2013 at $12.00. In approximately 2 months, Exact Sciences has returned 24.00% as of today's recent price of $14.88.
'Mad Money' Lightning Round: BB&T Is Fantastic
at The Street - Thu Jan 09, 5:00AM CST
Cramer has to wait and see about Michael Kors, he's not backing away from Franks International but he does not like Universal Display.
Jim Cramer's 'Mad Money' Recap: The Analysts Are Wrong
at The Street - Wed Jan 08, 7:00PM CST
They're trying to get you out of stocks at the very time you should be staying in, Cramer says.
2013 Report on the In-Vitro Diagnostic Substance Manufacturing Industry Features Players such as Hologic, Inc. and Quidel Corporation
M2 - Tue Jan 07, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dvwjc/invitro) has announced the addition of Supplier Relations US, LLC's new report "In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. The industry's revenue for the year 2012 was reported at $12.6 billion USD, with an estimated gross profit of 43.66%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $19.6 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. This 2013 year-end publication of In-Vitro Diagnostic Substance Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. At 173 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. This current report contains shipment data, inventory levels, international trade volume, and industry specific price indices available through September 2013. Industry analysts and Fortune 500 customers rely on this quarterly report to make accurate forecasts and planning in today's uncertain economy. Companies Mentioned: - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/7dvwjc/invitro Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 06, 3:14PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the J.P. Morgan Healthcare Conference.
Investors are betting against EXACT Sciences Corporation (EXAS), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:00AM CST
Investors are betting against EXACT Sciences Corporation (EXAS), Should You?
Look for Shares of Exact Sciences to Potentially Rebound after Yesterday's 4.32% Sell Off
Comtex SmarTrend(R) - Tue Dec 31, 5:35PM CST
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $11.53 to a high of $12.21. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $12.07 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Exelixis, Inc. (NASDAQ: EXEL), Cempra, Inc. (NASDAQ: CEMP), Exact Sciences Corporation (NASDAQ: EXAS), and Onconova Therapeutics, Inc. (NASDAQ: ONTX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Global Molecular Diagnostics in Cancer Testing: Market Report 2013
M2 - Tue Dec 17, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/wln6dv/molecular) has announced the addition of the "Global Molecular Diagnostics in Cancer Testing: Market Report 2013" report to their offering. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. "Global Molecular Diagnostics in Cancer Testing: Market Report 2013", describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The data also analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 5.1 Technology and Market Trends 5.2 M&A Activity 5.3 Partnerships 5.4 Competitive Analysis 5.5 SWOT Comparison of Business Models for Cancer Diagnostic Testing 5.6 Intellectual Property Rights 6. Reimbursement and Billing 6.1 Overview 6.3 Breast Cancer Tests 6.4 Colon Cancer Tests 6.5 Trends in Patient Care and Reimbursement 6.6 Revenue Threats 6.7 Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned: - Agendia - ArcticDx, Inc - Biodesix - bioTheranostics (AviaraDx) - Cancer Genetics, Inc - Clarient, Inc (GE Healthcare) - CombiMatrix Corporation - Epigenomics - Exact Sciences Corporation - Exagen Diagnostics, Inc - Exiqon - Ferrer inCode - Genomic Health, Inc - Genoptix, Inc - InterGenetics, Inc - LabCorp - Myriad Genetics, Inc - Nanostring - Neogenomics - Nuvera Biosciences - Orion Genomics - QIAGEN NV - Rosetta Genomics Ltd - Seegene - Sequenom, Inc - SABiosciences Corporation (Qiagen) - Source MDx - Targeted Molecular Diagnostics For more information visit http://www.researchandmarkets.com/research/wln6dv/molecular
